Skip to content


Oxervate (cenegermin) is a protein pharmaceutical. Cenegermin was first approved as Oxervate on 2017-07-06. It is used to treat keratitis in the USA. It has been approved in Europe to treat keratitis. The pharmaceutical is active against beta-nerve growth factor. In addition, it is known to target tumor necrosis factor receptor superfamily member 16.
Trade Name Oxervate
Common Name Cenegermin
Indication keratitis
Drug Class Growth factors
Get full access now